Board Member
Rhythm Pharmaceuticals, Inc. (RYTM)Board Member
Trevi Therapeutics, Inc. (TRVI)Equibles does not estimate personal net worth.
Get an email with a short summary when Trevi Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TRVI alertsJennifer Good is recorded as Board Member at Trevi Therapeutics, Inc. (TRVI) since June 11, 2025, CEO at Trevi Therapeutics, Inc. (TRVI) and Board Member at Rhythm Pharmaceuticals, Inc. (RYTM). The newest filing on record that lists Jennifer Good as Board Member at Rhythm Pharmaceuticals, Inc. (RYTM) is dated April 29, 2026. The proxy statement of Trevi Therapeutics, Inc. reports total compensation of $3,944,892 for Jennifer Good in fiscal 2025, including a base salary of $622,382. Disclosed compensation is on record for 8 fiscal years. Jennifer Good has spoken on 23 earnings calls and 2 other investor events across 1 company, most recently for Trevi Therapeutics, Inc. on September 16, 2026. Trevi Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Rhythm Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Trevi Therapeutics, Inc. includes Christopher Galletta (Chief Accounting Officer), Anne VanLent (Board Member), Dominick C. Colangelo (Board Member) and 1 other.
“And thank you for those of you that have hung around until the end of the day to hear us. So Trevi is a simple story. We're a single asset company focused in chronic cough indications.”
“Joining me today on this call are my colleagues Dr. James Gosella, our Chief Development Officer, Farrell Simon, our Chief Commercial Officer, and David Hastings, our Chief Financial Officer.”
“Joining me today on this call are my colleagues, Dr. James Casella, our chief development officer, Farrell Simon, our chief commercial officer, and David Hastings, our Chief Financial Officer.”
“Joining me today on this call are my colleagues, Dr. James Gosella, our chief development officer, Farrell Simon, our chief commercial officer, and David Hastings, our chief financial officer.”
“And for investors that are refreshing or digging in deeper on the Trevi story, can you just recap you know what's been going on with Trevi's core focus up to this point you've had a bit of news recently too like what are your main goals from going forward this year and beyond too yeah so Trevi came off 2025 was a very…”
2025-06-11–present
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CEO, Board Member
2025-06-11–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $622,382 | $3,944,892 |
| 2024 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $607,930 | $2,589,035 |
| 2023 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $596,924 | $1,687,298 |
| 2022 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $523,182 | $898,095 |
| 2021 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $505,961 | $1,527,439 |
| 2020 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $477,692 | $1,441,457 |
| 2019 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $434,615 | $2,810,719 |
| 2018 | Trevi Therapeutics, Inc. (TRVI) | President and Chief Executive Officer | $400,000 | $528,250 |
